Paper 09 - FIRST-IN-CLASS NON-CELLULAR TARGETING ANTIBODY-DRUG CONJUGATE (ADC), MICVOTABART PELIDOTIN (MICVO), IN PATIENTS (PTS) WITH ADVANCED SARCOMA

Author(s)

• 

  Gregory M. Cote, MD PhD (he/him/his)

  Associate Professor of Medicine
  Mass General Cancer Center, Massachusetts General Hospital
  Boston, Massachusetts, United States

  Slides

Co-Author(s)

• 

  Brian A. Van Tine, MD, PhD

  Professor of Medicine
  Washington University in St Louis School of Medicine
  St. Louis, Missouri, United States
• KC

  Katherine Clifton, MD

  MD Assistant Professor
  Washington University Medical Campus
  Louis, Missouri, United States
• DC

  Daniel Ernesto Castellano Gauna, MD

  MD
  Hospital Universitario 12 de Octubre Madrid
  Madrid, Madrid, Spain
• SS

  Shiraj Sen, MD

  MD
  Next Oncology
  Irving, Texas, United States
• RS

  Randy Sweis, MD

  MD
  University of Chicago Medical Center
  Chicago, Illinois, United States
• SR

  Sylvie Rottey, MD PhD

  Prof. Dr. Medical Oncologists
  Universitair Ziekenhuis Gent
  Gent, Brussels Hoofdstedelijk Gewest, Belgium
• AE

  Aymen Elfiky, MD

  MD
  Pyxis Oncology
  Boston, Massachusetts, United States
• OB

  Orlaith Bogg, MSc

  Clinical Scientist
  Pyxis Oncology
  Boston, Massachusetts, United States
• VA

  Victoria Attaya, BSc

  Senior Clinical Trial Manager
  Pyxis Oncology
  Boston, Massachusetts, United States
• HW

  Hongwei Wang, MD PhD

  MD
  Pyxis Oncology
  Boston, Massachusetts, United States
• 

  Alexander Spira, MD, PhD, FACP, FASCO

  MD
  NEXT Oncology
  Fairfax, Virginia, United States